Skip to content
Lonsurf(tipiracil)
Lonsurf (tipiracil) is a small molecule pharmaceutical. Tipiracil was first approved as Lonsurf on 2015-09-22. It is used to treat colorectal neoplasms in the USA. It has been approved in Europe to treat colorectal neoplasms.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
Trade Name
FDA
EMA
Combinations
Lonsurf
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tipiracil hydrochloride
+
Trifluridine
Tradename
Company
Number
Date
Products
LONSURFTaiho OncologyN-207981 RX2015-09-22
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lonsurfNew Drug Application2020-01-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
colorectal neoplasmsD015179
Agency Specific
FDA
EMA
Expiration
Code
TIPIRACIL HYDROCHLORIDE / TRIFLURIDINE, LONSURF, TAIHO ONCOLOGY
2026-02-22ODE-229
Patent Expiration
Patent
Expires
Flag
FDA Information
Tipiracil Hydrochloride / Trifluridine, Lonsurf, Taiho Oncology
104563992037-02-03U-2642
109600042037-02-03U-2642
95278332034-06-17DS, DP
104576662034-06-17DS, DP
RE462842029-09-22U-1751, U-2503
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
106 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179173115358
NeoplasmsD009369C8091110
Stomach neoplasmsD013274EFO_0003897C161516
Neoplasm metastasisD009362EFO_0009708111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD00023038111
Colonic neoplasmsD003110C18268
Rectal neoplasmsD012004448
Renal cell carcinomaD002292336
Pancreatic neoplasmsD010190EFO_0003860C25245
CholangiocarcinomaD018281C22.133
Breast neoplasmsD001943EFO_0003869C50213
Bile duct neoplasmsD00165022
Gallbladder neoplasmsD005706EFO_0004606C2322
Small cell lung carcinomaD05575211
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A11
Neuroendocrine tumorsD018358EFO_1001901D3A.811
Pancreatic ductal carcinomaD02144111
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTIPIRACIL
INNtipiracil
Description
Tipiracil is a member of the class of pyrimidones that is uracil substituted by chloro and (2-iminopyrrolidin-1-yl)methyl groups at positions 5 and 6 respectively. Used (as the hydrochloride salt) in combination with trifluridine, a nucleoside metabolic inhibitor, for treatment of advanced/relapsed unresectable colorectal cancer. It has a role as an antineoplastic agent and an EC 2.4.2.4 (thymidine phosphorylase) inhibitor. It is a pyrimidone, an organochlorine compound, a carboxamidine and a member of pyrrolidines. It is functionally related to a uracil. It is a conjugate base of a tipiracil(1+).
Classification
Small molecule
Drug classuracil type antineoplastics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl
Identifiers
PDB
CAS-ID183204-74-2
RxCUI1670304
ChEMBL IDCHEMBL235668
ChEBI ID
PubChem CID6323266
DrugBankDB09343
UNII IDNGO10K751P (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,160 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
16,275 adverse events reported
View more details